abexinostat   Click here for help

GtoPdb Ligand ID: 8366

Synonyms: CRA-024781 | CRA-24781 | PCI-24781
Compound class: Synthetic organic
Comment: Abexinostat is an investigational inhibitor of histone deacetylase enzymes (HDACs), with antitumour activity [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 104.04
Molecular weight 397.16
XLogP 1.88
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES ONC(=O)c1ccc(cc1)OCCNC(=O)c1oc2c(c1CN(C)C)cccc2
Isomeric SMILES ONC(=O)c1ccc(cc1)OCCNC(=O)c1oc2c(c1CN(C)C)cccc2
InChI InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
No information available.
Summary of Clinical Use Click here for help
Abexinostat is being eval;uated in a number of clinical trials, in solid and hematoligical malignancies, as monotherapy and in combination regimens. Click here to link to ClinicalTrials.gov's full list of abexinostat studies.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
HDAC inhibitors have shown clinical efficacy in AML, myelodysplastic syndrome and myeloproliferative neoplasms [3-4]. The HDAC inhibitor vorinostat was the first compound designed to inhibit HDACs to be approved for clinical use. HDAC inhibition increases acetylation of histone H3 and leads to downstream activation of the PI3K/Akt and MAPK/Ras signaling pathways and ultimately results in cell cycle arrest and apoptosis [2]. Mithraprabhu et al (2010) review the use of HDAC inhibitors in myeloproliferative neoplasms, and discuss the benefits of combination therapies with kinase inhibitors [3].